Linezolid (3 brand names, 3 dosage forms, 2 routes)
Available dosage forms: SOLUTION, TABLET, FOR SUSPENSION.
Routes of administration: INTRAVENOUS, ORAL.
Brand Names
- LINEZOLID
- LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
- ZYVOX
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: • Myelosuppression [see Warnings and Precautions ( 5.1)] • Peripheral and Optic Neuropathy [see Warnings and Precautions ( 5.2)] • Serotonin Syndrome [see Warnings and Precautions ( 5.3)] • Clostridioides difficile-Associated Diarrhea [see Warnings and Precautions ( 5.5)] • Lactic Acidosis [see Warnings and Precautions ( 5.7)] • Convulsions [see Warnings and Precautions ( 5.8)] • Rhabdomyolysis [see Warnings and Precautions ( 5.9)] • Hypoglycemia [see Warnings and Precautions ( 5.10)] Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [see Warnings and Precautions ( 5.11)]
Mechanism of Action
Linezolid is an antibacterial drug [see Microbiology ( 12.4 )].
Overdosage
In the event of overdosage, supportive care is advised, with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination of linezolid. In a Phase 1 clinical trial, approximately 30% of a dose of linezolid was removed during a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered. Data are not available for removal of linezolid with peritoneal dialysis or hemoperfusion. Clinical signs of acute toxicity in animals were decreased activity and ataxia in rats and vomiting and tremors in dogs treated with 3,000 mg/kg/day and 2,000 mg/kg/day, respectively.